Add Yahoo as a preferred source to see more of our stories on Google. The oral obesity drug market is set to reach $34.4bn in 2031 Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a ...
The oral obesity drug market is set to reach $34.4bn in 2031, GlobalData analysis predicts. Credit: Artem Stepanov / Shutterstock.com Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a ...
US clinical-stage biopharma CORXEL Pharmaceuticals has reported positive top-line Phase II data for CX11 (VCT220), its oral glucagon-like peptide-1 (GLP-1) receptor agonist for obesity and overweight.
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (“CORXEL”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for ...
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results